NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novavax Inc (NVAX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown promising revenue growth and strategic shifts, the financial performance is inconsistent, and analyst sentiment remains mixed. The technical indicators are neutral to slightly bullish, but there are no strong proprietary trading signals or significant catalysts to justify immediate action.
The MACD is positive but contracting, RSI is neutral at 56.645, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level (S1: 9.163), with resistance at R1: 11.401. Overall, the technical trend is cautiously bullish but lacks strong momentum.
Q4 revenue surged 67% YoY to $147 million, driven by collaborations and pipeline expansion.
Retail investor sentiment is highly optimistic, with a 580% increase in message volume on Stocktwits.
Strategic licensing agreement with Pfizer for Matrix-M adjuvant, indicating potential for high-margin revenue streams.
Net income and EPS dropped significantly YoY, indicating profitability challenges.
Analysts' price targets remain mixed, with some maintaining 'Underperform' or 'Sell' ratings.
Projected 2026 revenue is below analyst expectations, dampening long-term growth outlook.
In Q4 2025, revenue increased by 66.61% YoY to $147.1 million, and gross margin improved to 84.98% (up 43.94% YoY). However, net income dropped by -121.63% YoY to $17.5 million, and EPS fell by -121.57% YoY to $0.11, reflecting profitability issues despite revenue growth.
Analyst sentiment is mixed. Positive: H.C. Wainwright raised the price target to $16 with a Buy rating, citing the Pfizer agreement as a major step. Negative: BofA and Citi maintain Underperform and Sell ratings, with price targets of $8 and $7, respectively, citing concerns over development timing and revenue projections.
